Severe presentation of myelin oligodendrocyte glycoprotein antibody-associated disease: A case report

Neuroimmunology Reports Pub Date : 2024-06-10 DOI:10.1016/j.nerep.2024.100217

Dominique Comeau , Olivia Cull , Yanis Saheb , Remi Leblanc , Ludivine Chamard-Witkowski

{"title":"Severe presentation of myelin oligodendrocyte glycoprotein antibody-associated disease: A case report","authors":"Dominique Comeau , Olivia Cull , Yanis Saheb , Remi Leblanc , Ludivine Chamard-Witkowski","doi":"10.1016/j.nerep.2024.100217","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system. Relapse may be moderate to severe with an Expanded Disability Status Scale (EDSS) above 4.0 in half of patients, albeit most experience good to excellent motor recovery.</p></div><div><h3>Results</h3><p>Herein, we present an atypically severe case of MOGAD with an unusual clinical course. Patient initially presented with diplopia, lower limb motor deficit and hypoesthesia which rapidly deteriorated into quadriplegia. Corticosteroid regimen did not initially translate to significant clinical improvement (EDSS=9.0). At the 1 year follow up, patient had regained some mobility although with marked sequela (EDSS=6.5).</p></div><div><h3>Conclusion</h3><p>Although MOGAD is generally thought to be benign, it could also present with severe episodes.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"6 ","pages":"Article 100217"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X24000184/pdfft?md5=06ef7b6b09aee0cdcbb316f6cf60bb56&pid=1-s2.0-S2667257X24000184-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X24000184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system. Relapse may be moderate to severe with an Expanded Disability Status Scale (EDSS) above 4.0 in half of patients, albeit most experience good to excellent motor recovery.

Results

Herein, we present an atypically severe case of MOGAD with an unusual clinical course. Patient initially presented with diplopia, lower limb motor deficit and hypoesthesia which rapidly deteriorated into quadriplegia. Corticosteroid regimen did not initially translate to significant clinical improvement (EDSS=9.0). At the 1 year follow up, patient had regained some mobility although with marked sequela (EDSS=6.5).

Conclusion

Although MOGAD is generally thought to be benign, it could also present with severe episodes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

髓鞘少突胶质细胞糖蛋白抗体相关疾病的严重表现：病例报告

背景髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）是一种中枢神经系统炎症性脱髓鞘疾病。复发可能是中度至重度，半数患者的扩展残疾状态量表（EDSS）超过 4.0，但大多数患者的运动功能恢复良好至极佳。患者最初表现为复视、下肢运动障碍和感觉减退，并迅速恶化为四肢瘫痪。皮质类固醇治疗最初并没有带来明显的临床改善（EDSS=9.0）。在一年的随访中，患者恢复了一些活动能力，但后遗症明显（EDSS=6.5）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuroimmunology Reports

自引率

0.00%

发文量